Peptide PilotPeptide Pilot

mg ↔ units

Ipamorelin mg to units converter

Set your Ipamorelin vial concentration once, then flip in either direction between milligrams and U-100 syringe units.

Download Peptide PilotiPhone · Free to download

mg

0.200

units

20.0

mL

0.200

Concentration: 1.00 mg/mL (assumes a U-100 insulin syringe).

Ipamorelin is a short-acting injectable peptide people use to trigger a clean pulse of their own growth hormone, usually for recovery, sleep, and body composition. It mimics the gut hormone ghrelin at a single receptor, which keeps GH release pulse-like and avoids meaningful spikes in cortisol or prolactin. Studies show clear short-term GH increases after each injection, which is why it's commonly stacked with CJC-1295. This page covers reconstitution math and per-injection logging cadence.

How the Ipamorelin mg ↔ units converter works

This converter is a two-way bridge between dose mass (mg or mcg) and the unit count you actually draw on an insulin syringe. Once you set the Ipamorelin concentration of your current vial, you can type any mg value and read the units back, or type any unit count and read the mg back. It is the same math as the dose calculator, but bidirectional, which matters when you are checking a dose someone else recorded in units against a protocol written in mg.

The formula in both directions: mg = mL × concentration mg/mL, and units = mL × 100 on a U-100 syringe. With a 1 mg/mL Ipamorelin solution, 0.2 mg comes out to 20 units, and 20 units comes out to 0.2 mg. The converter handles the unit flip automatically so you never multiply or divide in your head while holding a syringe.

Concentration is the input that changes the answer most. A 2 mg vial diluted with 1 mL is twice as concentrated as the same vial diluted with 2 mL, which means the same dose draws half as many units. That is the single biggest source of converter confusion: a remembered unit count from an old vial does not transfer to a new vial reconstituted with different water volume.

Use the converter whenever a protocol or research note is written in one unit and your syringe is labeled in the other. It is also useful for sanity-checking that a planned titration step lands at a unit count you can read accurately on the syringe — under five units gets hard to read, over fifty starts crowding into the back third of a 1 mL syringe.

Why this matters for Ipamorelin

Ipamorelin's design is centered entirely on its selectivity profile, engineered to retain the potent growth hormone-releasing activity of earlier ghrelin mimetics while eliminating their common off-target effects. As a pentapeptide with the structure Aib-His-D-2-Nal-D-Phe-Lys-NH2, it is the smallest molecule in the growth hormone-releasing peptide (GHRP) family. Published binding studies consistently show that this structural minimalism contributes to a clean selectivity profile, distinguishing it from compounds like GHRP-6. The primary design goal was to achieve GH stimulation without concurrently elevating cortisol, prolactin, or adrenocorticotropic hormone (ACTH), a common characteristic of less selective ghrelin agonists.

The clinical pharmacology of Ipamorelin is most clearly understood by its contrast with GHRP-6, particularly regarding appetite. The intense hunger response that defines the user experience of GHRP-6 is notably absent with Ipamorelin, a direct result of its selective binding at the ghrelin receptor (GHSR-1a). This uncoupling of GH release from appetite stimulation represents a significant refinement in the development of GH secretagogues. Its mechanism is intended to amplify the natural pulsatile release of growth hormone from the pituitary, rather than creating a sustained and unnatural elevation that overrides endogenous rhythms.

Originating from research and development at Novo Nordisk in the late 1990s, ipamorelin was engineered with a specific goal: to create a potent growth hormone secretagogue with superior selectivity compared to its predecessors. Earlier compounds in the GHRP family, such as GHRP-6 and GHRP-2, were observed in studies to stimulate the release of other hormones, including cortisol and prolactin. The development path for ipamorelin, documented under the research code NNC 26-0161, focused on isolating the GH-releasing activity while minimizing or eliminating these off-target effects, representing a significant step in the refinement of synthetic ghrelin mimetics.

Ipamorelin mechanism in plain English

Ipamorelin functions as a synthetic agonist for the ghrelin receptor, scientifically known as the growth hormone secretagogue receptor type 1a (GHSR-1a). Upon administration, it travels to the pituitary gland and binds to these receptors, mimicking the action of ghrelin, the endogenous hormone responsible for initiating GH release pulses. The activation of GHSR-1a initiates an intracellular signaling cascade that results in the synthesis and secretion of stored growth hormone from somatotroph cells.

The crucial aspect of its mechanism is its high specificity for the GHSR-1a. Unlike first- and second-generation GHRPs, Ipamorelin's molecular structure was intentionally refined to minimize or avoid interaction with other receptor systems. This selectivity prevents the downstream release of other pituitary hormones such as prolactin and ACTH, and consequently avoids stimulating the adrenal gland to produce cortisol, which are widely documented side effects of its predecessors.

The high selectivity of ipamorelin is a central aspect of its mechanism. While it functions, like other GHRPs, by mimicking the action of ghrelin, its molecular design results in a more discrete signaling cascade. Upon binding to the GHS-R1a receptor, it stimulates the pituitary somatotrophs to release a pulse of growth hormone. Unlike less selective compounds, it does not demonstrate a significant affinity for other receptors or trigger substantial cross-reactivity that would lead to a release of cortisol or prolactin at typical research dosages. This allows researchers to monitor the downstream effects attributable primarily to GH itself, providing a cleaner dataset for analysis and tracking over time.

Tracking Ipamorelin unit counts

For anyone documenting an Ipamorelin protocol, the most critical variable to log is the exact timing of each dose. The selectivity advantage of this peptide is best observed by analyzing trends over multiple weeks, and this analysis is only valid if dose timing is consistent. Inconsistent scheduling can introduce confounding variables that make it difficult to evaluate the protocol's adherence. When Ipamorelin is part of a stack, such as with CJC-1295, each compound must be recorded as a separate entry in the log to permit accurate inventory tracking and ensure the remaining quantity in each vial is known.

For those engaged in detailed personal data collection, logging the prandial state at the time of each ipamorelin administration provides a critical layer of information. Beyond simply recording the date, time, and dosage, adding a note such as 'Fasted >3 hours' or 'Post-prandial <90 minutes' creates a more robust dataset. Over time, these records allow an individual to analyze and observe any correlations between administration timing relative to meals and the tracked outcomes. This level of detail enables a more sophisticated review of the data, helping to identify patterns that might otherwise be obscured by metabolic variables like insulin levels.

Common Ipamorelin conversion mistakes

  • Administering doses at inconsistent times of day, which compromises the ability to observe long-term trends related to its selective action.
  • Logging a combination like Ipamorelin/CJC-1295 as a single dose entry, which inevitably causes errors in vial inventory management for each separate peptide.
  • Misinterpreting the designed absence of an appetite spike as a sign that the peptide is inactive or low in potency.
  • Scheduling administration shortly after a meal containing carbohydrates or fats, thereby blunting the potential GH pulse via insulin release.
  • Failing to document the reconstitution date and diluent volume, which makes future dose calculations and expirations impossible to track accurately.
  • Assuming ipamorelin produces identical secondary hormonal effects as older compounds like GHRP-6, thereby failing to account for its selective nature in study design.
  • Not documenting the timing of administration in relation to meals, which introduces insulin fluctuations as an uncontrolled variable.
  • Neglecting to use a calculator to verify dose calculations after reconstitution, leading to inconsistent administration amounts that compromise data integrity.

Frequently asked questions about Ipamorelin mg ↔ units

What is the primary distinction between Ipamorelin and GHRP-6?
The defining distinction is selectivity. Ipamorelin was developed specifically to stimulate growth hormone release with high potency while avoiding the significant increases in appetite, cortisol, and prolactin that are characteristic of older secretagogues like GHRP-6. This targeted action results from its refined molecular structure and specific binding profile.
Why is Ipamorelin often studied in combination with CJC-1295 without DAC?
This combination is studied because it targets two separate pituitary receptors to synergistically amplify GH release. Ipamorelin acts on the ghrelin receptor while CJC-1295 (no DAC) acts on the GHRH receptor. Activating both pathways at once generates a more robust GH pulse than using either peptide alone, while still honoring the body's natural pulsatile rhythm.
How many units are required for a 200 mcg dose from a 2 mg vial reconstituted with 2 mL?
A 2 mg vial holds 2,000 micrograms of peptide. When reconstituted with 2 mL of bacteriostatic water, the final concentration becomes 1,000 mcg per mL. To draw a 200 mcg dose, you need 0.2 mL of the solution, which measures as exactly 20 units on a U-100 insulin syringe.
Does Ipamorelin's smaller peptide structure influence its properties?
Yes, its structure as a pentapeptide makes it one of the smallest molecules in the GHRP class. This minimalism is a key element of its design, contributing to its high binding specificity for the ghrelin receptor and its 'clean' profile, which minimizes the off-target receptor interactions seen with larger, more complex secretagogues.
Is the lack of a hunger response a sign that Ipamorelin is not working?
No, the absence of hunger is a designed-in feature and a direct confirmation of Ipamorelin's selectivity. It successfully uncouples the GH-releasing action from the separate ghrelin-mediated hunger signaling that is a hallmark of GHRP-6. The peptide's activity is determined by its effect on GH levels, not by the presence or absence of secondary effects.
What is the significance of scheduling doses in a fasted state?
Administering Ipamorelin on an empty stomach is a standard element of research protocols because the presence of food, especially carbohydrates and fats, can trigger the release of insulin. Insulin can in turn stimulate somatostatin, a hormone that inhibits growth hormone secretion from the pituitary. Dosing in a fasted state avoids this potential blunting effect on the GH pulse.
Why is ipamorelin administration often timed around fasting in research settings?
Many research protocols document ipamorelin administration during a fasted state due to the interaction between insulin and growth hormone. The GH pulse stimulated by ipamorelin can be partially blunted by elevated insulin levels, which typically occur after consuming a meal, especially one rich in carbohydrates. To study its effects under consistent physiological conditions, researchers often schedule administrations at times when insulin levels are expected to be at a baseline, such as upon waking or several hours after a meal. Logging the prandial state at the time of administration is a way to track this variable.
What specifically makes ipamorelin a 'selective' GH secretagogue?
Ipamorelin is considered selective because it was specifically designed to stimulate growth hormone release with minimal to no effect on other hormones like cortisol and prolactin at standard research dosages. Its development by Novo Nordisk in the 1990s aimed to improve upon earlier GHRPs, which were observed to cause elevations in these other hormones. This selectivity allows researchers to study the effects of GH elevation in a more isolated manner, without the confounding variables of simultaneous increases in stress hormones or prolactin.
Does the selectivity of ipamorelin change with the dose amount?
In scientific literature, the selectivity of ipamorelin for the GH axis is often noted as being dose-dependent. While standard research doses are observed to have minimal impact on cortisol and prolactin, studies involving very high, supramaximal doses have sometimes documented a loss of this selectivity. This means that at extremely large dosages, some stimulation of cortisol and prolactin might be observed. Therefore, when researchers plan a study, the dosage is a critical parameter to control and document, as it directly relates to the compound's selective properties.

Related on Peptide Pilot

Save your Ipamorelin vial in the app

Download on the App Store
Get the App